Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
fda
life sciences
national blog main
amgen
biotech
boston blog main
boston top stories
national
san francisco blog main
san francisco top stories
abaloparatide
acute hepatic porphyrias
akin akinc
alder biopharmaceuticals
alnylam pharmaceuticals
aminolevulinic acid
boston
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
david rind
detroit blog main
detroit top stories
drugs
eli lilly
episodic migraine
eptinezumab
erenumab
europe blog main
europe top stories
european commission
food and drug administration
fremanezumab
galcanezumab
givosiran
indiana blog main
indiana top stories
institute for clinical and economic review
What
approval
3
×
drug
nod
3
×
amgen
developed
fda
medicine
ago
alnylam
amgen’s
candidates
carries
class
europe
european
gets
head
heart
indicated
interference
marketing
medicines
migraine
new
osteoporosis
pain
pharmaceuticals
preventive
quick
raise
risk
rna
rnai
second
seek
speedy
starts
warning
weeks
wins
Language
unset
Current search:
nod
×
approval
×
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines